#USA #Draper #AI-enabled #Xenter #TechMed™

Xenter Secures $58.25 Million in Series B Funding

In a significant move for the healthcare tech landscape, Xenter, Inc., a pioneering TechMed™ company, announced the completion of its Series B financing round, successfully raising $58.25 million as of June 30, 2026. This funding is set to accelerate the commercial launch of Xenter's innovative healthcare intelligence platform designed for diagnostic evaluations along with their revolutionary XenFi™ wireless ecosystem.

Key Developments and Investments

The financing attracted a mix of existing shareholders, influential family offices, and healthcare investors who are aligned with Xenter's vision for transforming healthcare data management in clinical settings, such as hospitals and physician offices. According to Richard J. Linder, Founder and CEO of Xenter, this funding not only provides essential capital but also signals strong investor confidence in the company’s long-term strategy to reshape how healthcare technologies interact and utilize data for improved patient outcomes.

With this injection of funds, Xenter will focus on several key areas:

• - Commercial Launch: This funding will enable the initial market introduction of their diagnostics business unit.
• - Further Development: Continued innovation of proprietary technologies within the TechMed platform.
• - Manufacturing Expansion: Investment in manufacturing infrastructure to meet growing demands.
• - Clinical and Regulatory Initiatives: Progress in clinical testing and compliance with regulatory standards.

Innovations on the Horizon

The raised capital will not only aid in facilitating the operational needs of Xenter but also allow them to initiate clinical testing of their Guru™ dual sensor physiology guidewire, which is integral to Transcatheter Aortic Valve Replacement (TAVR) procedures. Linder emphasizes that the Xenter's technology aims to rectify the traditional disconnect in healthcare systems, often characterized by fragmented information that is difficult to navigate.

Xenter's commitment lies in developing a robust integrated intelligence platform that seamlessly unites medical devices, diagnostics, and artificial intelligence. According to Linder, the ultimate goal is to enhance clinical decision-making while ensuring patients maintain control over their healthcare data.

Strengthening Governance with New Talent

In conjunction with this financial milestone, Xenter has appointed Linda Vega to its Board of Directors. Vega brings extensive expertise from her background in banking, finance, and corporate governance, which is expected to be invaluable during this phase of growth. Her guidance will bolster Xenter’s strategic endeavors as they advance in the tech healthcare space.

Linda expressed her excitement about joining the board, citing the opportunity to collaborate with legendary leaders in the life sciences sector. Her experience with various organizations across multiple dimensions of financial strategy and governance will be instrumental as Xenter embarks on its ambitious expansion plans.

About Xenter

Founded in 2020 and headquartered in Draper, Utah, Xenter is creating a new category where medical devices converge with data infrastructure and clinical AI. The company’s innovative approach emphasizes Physical Intelligence™ (PI), capturing real-time, high-fidelity data to enrich the healthcare landscape. Through an expansive library of clinical, procedural, and diagnostic data, Xenter empowers patients, healthcare providers, and systems to make informed decisions towards optimal care.

To learn more about Xenter and their groundbreaking technology, visit www.xenter.io.

In a fast-evolving tech landscape where healthcare needs are increasingly complex, Xenter's commitment to innovation and integration positions it well for future growth and development in the healthcare technology sector.